CD4 and inflammatory bowel disease: Treatment of mice in which IBD had been induced by adoptive T cell transfer with the selective SOCE inhibitor CM4620 attenuated the clinical course of colitis, which was associated with reduced neutrophil infiltration of the LP and decreased IFNγ and TNFα production by CD4+ T cells, suggesting that SOCE inhibition may be a new treatment option for IBD.